期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
Aberrantly Methylated MGMT,hMLH1 and hMSH2 in Tumor and Serum DNA of Gliomas Patients
1
作者 Changqing Zheng Shouping Ji +7 位作者 Feng Gong anming li Junli Tai Subuo li Yingli Wang Hongyu Chang Hongwei Gao Yangpei Zhang 《Chinese Journal of Clinical Oncology》 CSCD 2009年第1期42-46,共5页
OBJECTIVE This study is to investigate the prevalence ofpromoter CpG island methylation of O^6-methylguananine-DNAmethyltransferase (MGMT), mismatch repair genes (hMLH1 andhMSH2) in both tumor and serum samples of gli... OBJECTIVE This study is to investigate the prevalence ofpromoter CpG island methylation of O^6-methylguananine-DNAmethyltransferase (MGMT), mismatch repair genes (hMLH1 andhMSH2) in both tumor and serum samples of gliomas.METHODS Methylation-specific PCR (MSP) was employed todetect promoter CpG island methylation of the MGMT, hMLH1and hMSH2 genes in 39 samples taken from surgery and 32samples of pretreatment serum all from the patients with gliomas.RESULTS Promoter CpG island methylation of MGMT, hMLH1and hMSH2 was detected and the results were 46.2%, 10.3% and20.5%, respectively in tumor DNA of the cases with gliomas,and 40.6%, 9.4% and 18.8%, respectively in serum DNA of thecases. The methylation pattern in primary tumor and serum wasfound to be concordant in matched tissue and serum samplesof 21 patients. In the cases with positive result of methylationfor MGMT, hMLH1 and hMSH2 in tumor tissues, the results ofdetection for those in the paired serum sample were 77.8% (7/9),66.7% (2/3) and 75.0 % (3/4), respectively. False positive resultswere not obtained in any of the patients who did not exhibitmethylation. No association was found between the promotermethylation of MGMT, hMLH1, and hMSH2 genes in primarygliomas and gender, age, localization, grade of malignant or tumorstage.CONCLUSION Promoter CpG island methylation is a frequentevent in gliomagenesis. Methylation analysis appears to bea promising predictive factor of the prognosis for the gliomapatients treated with alkylating drugs and a noninvasive tumormarker in serum DNA. 展开更多
关键词 HMSH2基因 HMLH1 血清DNA 肿瘤DNA MGMT 脑胶质瘤 异常甲基化 CpG岛甲基化
下载PDF
Simple synthesis of BiOI/ZnO/rGO for efficient photocatalytic degradation of antibiotic chloramphenicol under visible light
2
作者 Zihan Zhu Feng Guo +2 位作者 anming li Weichao Xu Xuehan Zhang 《Journal of Environmental Sciences》 SCIE EI CAS CSCD 2023年第12期65-76,共12页
BiOI/ZnO/rGO(reduced graphene oxide) composite photocatalyst was fabricated using a simple one-step hydrothermal process and applied to the degradation of antibiotic chloramphenicol(CAP). By tuning the Bi/Zn ratios, t... BiOI/ZnO/rGO(reduced graphene oxide) composite photocatalyst was fabricated using a simple one-step hydrothermal process and applied to the degradation of antibiotic chloramphenicol(CAP). By tuning the Bi/Zn ratios, the structure and photoelectric properties of the catalyst were investigated and characterized in terms of their morphological, structural, optical and photoelectrochemical properties. The as-synthesized composite photocatalysts are well-crystalline, uniform dispersion and exhibit good photocatalytic properties.The photocatalytic degradation rate of CAP by BiOI/ZnO/rGO composite is 8.1 times and 1.8times that of BiOI and ZnO, respectively. The photocatalytic mechanism studies revealed that the synergistic effect between rGO and BiOI/ZnO can effectively separate photogenerated electron–hole, enhance photocurrents and conductivity, and improve charge carrier densities. Moreover, BiOI/ZnO/rGO possesses good stability and reusability that the degradation efficiency remained above 80% even after 5 recycling. This study reveals that both the introduction of rGO and heterostructure construction between BiOI and ZnO play a crucial role in their photoelectrochemical and photocatalytic properties. 展开更多
关键词 BiOI/ZnO/rGO(reduced graphene oxide) PHOTODEGRADATION CHLORAMPHENICOL Visible light
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部